Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 04, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 350,000 ordinary shares of 25 pence each.
- Purchase Price: 1,435.66 pence per share.
- Treasury Holdings: 187,031,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,797,295,130 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 350,000 shares on August 04, 2006, which were immediately placed into Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (350,000 shares at 1,435.66 pence) against the company's cash position in broader financial reports.
- Confirm the updated total share count and Treasury holdings in subsequent filings to track the ongoing buyback program.
- Note that this filing is a notification of a specific transaction and does not replace quarterly or annual financial performance reports.